As Neola Medical reports its second quarter of 2023, much of the focus is on market preparations. Intensive work is underway with technical verification studies while the company is also preparing for both a preclinical and a clinical study. BioStock contacted CEO...
Press communication Lund, Sweden, August 17, 2023 This is a translation of the Swedish press release published 2023-08-17 Neola Medical AB (the “Company”) has appointed ABG Sundal Collier (“ABGSC”) as liquidity provider for the Company’s shares listed on Nasdaq...
Yesterday, Neola Medical released the Q2 report for 2023. In connection, CEO Hanna Sjöström and CFO Christian Gyllenberg presented the report in a videoconference. Apart from presenting the company’s financials and the significant events from this quarter, they...
This is a translation of the Swedish press release published 2023-08-15, 08.00 CEST Neola Medical AB (publ) today publishes the Q2 report of 2023 (in Swedish). The report is available at the company’s website and is attached to the press release. During the...
Press communication Lund, Sweden, August 8, 2023 This is a translation of the Swedish press release published 2023-08-08 Neola Medical AB (publ) announces today that the company’s trademark, Neola®, has been registered in the U.S, the company’s most important market....
This is a translation of the Swedish press release published 2023-08-07 Neola Medical AB (publ) invites to presentation of the Q2-report of 2023, Tuesday August 15, 2023, at 11am (CET, 11.00). The presentation will be held online as a video conference. The Q2-report...
